[11C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: A PET study using Bcrp TGEM knockout rats

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 3-4, 2013, Pages 520-525

  Hosten, Benoit ^a   Boisgard, Raphaël ^b,c   Jacob, Aude ^a   Goutal, Sébastien ^b   Saubaméa, Bruno ^a   Dollé, Frédéric ^b   Scherrmann, Jean Michel ^a   Cisternino, Salvatore ^a,b   Tournier, Nicolas ^b  

^a INSERM   (France)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

ABC transporters; Befloxatone; Blood brain barrier; Compensation; Monoamine oxidase A (MAO A); Positron emission tomography

Indexed keywords

BEFLOXATONE C11; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RADIOISOTOPE; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, RAT; BEFLOXATONE; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SLICE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; IMAGING; MALE; MICROVASCULATURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; BRAIN; GENETICS; METABOLISM; TRANSGENIC RAT; WISTAR RAT; ABC-TRANSPORTERS; COMPENSATION; MONOAMINE OXIDASE A (MAO-A);

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; MALE; OXAZOLES; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, TRANSGENIC; RATS, WISTAR;

ABC-TRANSPORTERS; BEFLOXATONE; BLOOD-BRAIN BARRIER; COMPENSATION; MONOAMINE OXIDASE A (MAO-A); POSITRON EMISSION TOMOGRAPHY;

EID: 84883682829     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.015     Document Type: Article

References (41)

1. S. Agarwal, and W.F. Elmquist Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance Mol. Pharm. 9 2012 678 684
2. S. Agarwal, Y. Uchida, R.K. Mittapalli, R. Sane, T. Terasaki, and W.F. Elmquist Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice Drug Metab. Dispos. 40 2012 1164 1169
3. J.P. Bankstahl, M. Bankstahl, K. Römermann, T. Wanek, J. Stanek, A.D. Windhorst, and M. Fedrowitz Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study Drug Metab. Dispos. 41 2013 754 762
4. S. Cisternino, C. Mercier, B. Fanchon, F. Roux, and J.M. Scherrmann Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier Cancer Res. 64 2004 3296 3301 (Pubitemid 38581436)
5. N.A. De Vries, J. Zhao, E. Kroon, T. Buckle, J.H. Beijnen, and O. van Tellingen P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan Clin. Cancer Res. 13 2007 6440 6449 (Pubitemid 350075034)
6. N.A. De Vries, T. Buckle, J. Zhao, J.H. Beijnen, J.H. Schellens, and O. van Tellingen Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP Invest. New Drugs 30 2012 443 449
7. S. Demphel, B. Kuhnast, A. Damont, S. Le Helleix, J. Froissant, F. Marguet, F. Puech, and F. Dollé A novel radiosynthesis of the MAO ligand befloxatone: preparation of [methoxy-11C]befloxatone J. Label Compd. Radiopharm. 56 2013 S107
8. F. Dollé, H. Valette, Y. Bramoulle, I. Guenther, C. Fuseau, C. Coulon, and C. Lartizien Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A Bioorg. Med. Chem. Lett. 13 2003 1771 1775 (Pubitemid 36561162)
9. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, and A. Dahlin Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
10. K. Hoffmann, and W. Löscher Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats Epilepsia 48 2007 631 645 (Pubitemid 46587614)
11. S. Hori, S. Ohtsuki, M. Tachikawa, N. Kimura, T. Kondo, M. Watanabe, E. Nakashima, and T. Terasaki Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s) J. Neurochem. 90 2004 526 536 (Pubitemid 38989383)
12. Hoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T., Ohtsuki, S., Terasaki, T., 2013. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. (Epub ahead of print).
13. M.R. Jablonski, D.A. Jacob, C. Campos, D.S. Miller, N.J. Maragakis, P. Pasinelli, and D. Trotti Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS Neurobiol. Dis. 47 2012 194 200
14. P. Kannan, C. John, S.S. Zoghbi, C. Halldin, M.M. Gottesman, R.B. Innis, and M.D. Hall Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications Clin. Pharmacol. Ther. 86 2009 368 377
15. K. Kawamura, T. Yamasaki, J. Yui, A. Hatori, F. Konno, K. Kumata, T. Irie, T. Fukumura, K. Suzuki, I. Kanno, and M.R. Zhang In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib Nucl. Med. Biol. 36 2009 239 246
16. C. Kuntner, J.P. Bankstahl, M. Bankstahl, J. Stanek, T. Wanek, G. Stundner, and R. Karch Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET Eur. J. Nucl. Med. Mol. Imag. 37 2010 942 953
17. A. Lazarowski, L. Czornyj, F. Lubienieki, E. Girardi, S. Vazquez, and C. D'Giano ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy Epilepsia 48 2007 140 149 (Pubitemid 47512215)
18. C. Leroy, V. Bragulat, I. Berlin, M.C. Grégoire, M. Bottlaender, D. Roumenov, and F. Dollé Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone J. Clin. Psychopharmacol. 29 2009 86 88
19. F. Lin, S. Marchetti, D. Pluim, D. Iusuf, R. Mazzanti, J.H. Schellens, J.H. Beijnen, and O. van Tellingen Abcc4 together with Abcb1 and Abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues Clin. Cancer Res. 19 2013 2084 2095
20. C. Luna-Tortós, M. Fedrowitz, and W. Löscher Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 55 2008 1364 1375
21. S. Mairinger, T. Erker, M. Muller, and O. Langer PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo Curr. Drug Metab. 12 2011 774 792
22. G. Merino, A.I. Alvarez, M.M. Pulido, A.J. Molina, A.H. Schinkel, and J.G. Prieto Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion Drug Metab. Dispos. 34 2006 690 695
23. T. Mizuno, M. Fukudo, T. Terada, T. Kamba, E. Nakamura, O. Ogawa, K. Inui, and T. Katsura Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics Drug Metab. Pharmacokinet. 27 2012 631 639
24. B. Saubaméa, V. Cochois-Guégan, S. Cisternino, and J.M. Scherrmann Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression J. Cereb. Blood Flow Metab. 32 2012 81 92
25. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, and C.A. Mol Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502 (Pubitemid 24153990)
26. E.G. Schuetz, D.R. Umbenhauer, K. Yasuda, C. Brimer, L. Nguyen, M.V. Relling, J.D. Schuetz, and A.H. Schinkel Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes Mol. Pharmacol. 57 2000 188 197 (Pubitemid 30033275)
27. J. Shen, A.M. Carcaboso, K.E. Hubbard, M. Tagen, H.G. Wynn, J.C. Panetta, C.M. Waters, M.A. Elmeliegy, and C.F. Stewart Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid Cancer Res. 69 2009 5885 5892
28. S. Shen, D. Callaghan, C. Juzwik, H. Xiong, P. Huang, and W. Zhang ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease J. Neurochem. 114 2010 1590 1604
29. Y. Takada, M. Ogawa, H. Suzuki, and T. Fukumura Radiosynthesis of [2-(11)C-carbonyl]dantrolene using [(11)C]phosgene for PET Appl. Radiat. Isot. 68 2010 1715 1720
30. T. Takashima, C. Wu, M. Takashima-Hirano, Y. Suzuki, H. Wada, M. Kuhnast, F. Kusuhara, Y. Sugiyama, and Y. Watanabe Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807 J. Nucl. Med. 54 2013 267 276
31. N. Tournier, H. Valette, M.A. Peyronneau, W. Saba, S. Goutal, B. Kuhnast, F. Dollé, J.M. Scherrmann, S. Cisternino, and M. Bottlaender Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening J. Nucl. Med. 5 2011 415 423
32. N. Tournier, X. Declèves, B. Saubaméa, J.-M. Scherrmann, and S. Cisternino Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology Curr. Pharm. Des. 17 2011 2829 2842
33. H. Valette, M. Bottlaender, F. Dollé, C. Coulon, M. Ottaviani, and A. Syrota Acute inhibition of cardiac monoamine oxidase A after tobacco smoke inhalation: validation study of [11C]befloxatone in rats followed by a positron emission tomography application in baboons J. Pharmacol. Exp. Ther. 314 2005 431 436 (Pubitemid 41058281)
34. M.L. Vlaming, J.S. Lagas, and A.H. Schinkel Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice Adv. Drug Deliv. Rev. 61 2009 14 25
35. T. Wanek, C. Kuntner, J.P. Bankstahl, M. Bankstahl, J. Stanek, M. Sauberer, and S. Mairinger A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer Eur. J. Nucl. Med. Mol. Imag. 39 2012 149 159
36. T. Wanek, C. Kuntner, J.P. Bankstahl, S. Mairinger, M. Bankstahl, J. Stanek, and M. Sauberer A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier J. Cereb. Blood Flow Metab. 32 2012 2002 2011
37. T. Wang, S. Agarwal, and W.F. Elmquist Brain distribution of cediranib is limited by active efflux at the blood-brain barrier J. Pharmacol. Exp. Ther. 341 2012 386 395
38. G. Xiao, C. Black, G. Hetu, E. Sands, J. Wang, R. Caputo, and E. Rohde Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates Drug Metab. Dispos. 40 2012 779 787
39. H. Xiong, D. Callaghan, A. Jones, J. Bai, I. Rasquinha, C. Smith, and K. Pei ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides J. Neurosci. 29 2009 5463 5475
40. S. Yousif, C. Marie-Claire, F. Roux, J.M. Scherrmann, and X. Declèves Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy Brain Res. 1134 2007 1 11 (Pubitemid 46156932)
41. Zhang, L., Spencer, K.L., Voruganti, V.S., Jorgensen, N.W., Fornage, M., Best LG., Brown-Gentry, K.D., et al., 2013. Association of functional polymorphism rs2231142 (Q141K) in the abcg2 gene with serum uric acid and gout in 4 US populations: the PAGE study. Am J Epidemiol. (Epub ahead of print).